26.08.2021 • News

SK Capital Buys Deltech Businesses

Private equity company SK Capital Partners has purchased a majority stake in the monomers, polymers and European businesses of Deltech Holdings. Financial terms and the size of the stake were not disclosed, although Deltech’s founder and current president and CEO Bob Elefante is retaining a “significant” share and will remain actively involved in the company, including serving on the board of directors.

“Deltech is a world leader in the production of high-performance aromatic monomers and specialized crystal polystyrene,” said Mario Toukan, managing director at SK Capital. “Deltech offers an attractive product portfolio with leading market positions in niche technologies. Their portfolio includes vinyl toluene, divinyl benzene and para methyl styrene, in addition to their specialty crystal polystyrene. Deltech’s products deliver critical attributes to products across a diverse set of end markets, including coatings and adhesives resins, ion exchange resins, insulation and molded composites, to name a few.”

The acquisition includes Deltech’s headquarters and manufacturing facility in Baton Rouge, Louisiana, as well as additional manufacturing plants in Troy, Ohio, and Haverhill in the UK, along with its global field operations. The company employs 135 people.

SK Capital managing director Jonathan Borell said the company plans to expand commercial applications for Deltech’s highly specialized monomers and polymers.

Author: Elaine Burridge, Freelance Journalist

SK Capital Partners has purchased a majority stake in the monomers, polymers...
SK Capital Partners has purchased a majority stake in the monomers, polymers and European businesses of Deltech Holdings. The acquisition includes Deltech’s headquarters and manufacturing facility in Baton Rouge, Louisiana, as well as plants in Troy, Ohio and Haverhill in the UK. (c) Deltech

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.